Back to LCT Homepage Targeting Huntington's Disease, Stroke, Type 1 Diabetes and Haemophilia
Living Cell Technologies
LCT - Living Cell Technologies

News

News updates: Subscribe
Unsubscribe

Archive

July 22, 2008
LCT Reports Clinical Benefits
>more
July 17, 2008
LCT Hosts Seminar of World Leaders
>more
July 14, 2008
LCT Quarterly Newsletter
>more
July 11, 2008
Transcript of LCT interview with The Wall Street
>more
June 26, 2008
LCT Informed of Progress for Diabetes Clinical Trial
>more
 

News

LCT appoints CEO as Company Heads into New
Phase of Development
January 24, 2007

Living Cell Technologies Ltd (ASX:LCT) today announced that its founder and CEO will step aside due to health reasons to allow the succession of Dr Paul LJ Tan, to spearhead a new strategy and direction for the company as it enters clinical trials in 2007.

This change marks the transition for LCT from a research and development company, into clinical development and commercialisation of its xeno cell transplant therapies. The Board of Directors are delighted that Dr Tan, previously Managing Director of the NZ operations, has accepted the position to drive a very exciting and new period of growth for the company.

Related Document
Download ( = 44Kb )

LCT - Living Cell Technologies

Q & A

What is xenotransplantation?
The use of living animal cells, tissues or organs in human therapeutics. >more

What is DiabeCell?
DiabeCell is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. >more

What is NeurotrophinCell?
A choroid plexus (brain) cell product with the potential to treat diseases of the nervous system such as Huntington's disease and stroke. >more

What is LCT's encapsulation technology?
The living cells are covered in a seaweed-derived coating (alginate encapsulation) to form capsules which eliminate the
need for toxic immunosuppressant drugs and allow the release of beneficial factors. >more
 
HomeContactSitemapLegalsPrivacy
  
graphic design and website design - PDF Communications Ltd